Verona Pharma PLC
17Patents
16Active
17Granted
51Portfolio score
Filing activity: Feb 24, 2004 → Nov 15, 2024 · 1 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9062047B2 | Crystalline form of pyrimido[6,1-A] isoquinolin-4-one compound | Human Necessities | 14 | Active |
| US7378424B2 | Derivatives of pyrimido[6, 1-A]isoquinolin-4-one | Human Necessities | 14 | Expired |
| US8242127B2 | Derivatives of pyrimido[6,1-A]isoquinolin-4-one | Human Necessities | 13 | Active |
| US9700558B2 | Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist | Human Necessities | 10 | Active |
| US9717732B2 | Drug combination | Human Necessities | 10 | Active |
| US9956171B2 | Liquid inhalation formulation comprising RPL554 | Human Necessities | 8 | Active |
| US10463665B2 | Salt of a pyrimido[6,1-A]isoquinolin-4-one compound | Human Necessities | 7 | Active |
| US10471063B2 | Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist | Human Necessities | 7 | Active |
| US10945950B2 | Liquid inhalation formulation comprising RPL554 | Human Necessities | 6 | Active |
| US10710998B2 | Compound and process | Chemistry; Metallurgy | 6 | Active |
| US10864213B2 | Treatment | Human Necessities | 6 | Active |
| US11491155B2 | Salt of a pyrimido[6,1-A]isoquinolin-4-one compound | Human Necessities | 5 | Active |
| US11759467B2 | Treatment | Human Necessities | 4 | Active |
| US12168011B2 | Formulation production process | Human Necessities | 2 | Active |
| US12251384B1 | Particulate composition | Human Necessities | 1 | Active |
| US12194045B1 | Particulate composition | Human Necessities | 1 | Active |
| US12409180B2 | Formulation production process | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.